29 results about "Pathology" patented technology

Methods and compositions for diagnosing and treating glaucoma are disclosed.

The invention discloses a method for judging the sex of trachinotus ovatus at an early stage. Young trachinotus ovatus is selected, the left body wall is cut off, sex gland is found out, characteristics of the sex gland are observed in situ, the sex gland is taken out and dissected, the characteristics of the dissection face of the sex gland are observed, and the sex of the trachinotus ovatus is judged by analyzing the characteristics of the sex gland According to the method, the instrument is simple, operation is rapid, the result is accurate, toxic chemical agents are not used, the method for judging the sex of the trachinotus ovatus at the early stage is convenient to carry out efficient, and reliable materials can be provided for molecular marker research for further searching for sex specialty of the trachinotus ovatus.

The invention relates to a pulmonary tuberculosis variation activity marker, a kit, a method and a model construction method, and the pulmonary tuberculosis variation activity marker is characterized in that the pulmonary tuberculosis variation activity marker is a plasma protein biomarker in a blood sample, and the plasma protein biomarker is a combined marker comprising one or more of C1QB protein and CCL19 (MIP3B) protein; a combined marker of C1QB and CCL19 (MIP3B) is used as a biomarker for detecting the activity of pulmonary tuberculosis for the first time, a rapid diagnosis model for detecting the activity of pulmonary tuberculosis is constructed, a new direction is provided for clinical diagnosis of tuberculosis, and as a technical conception for diagnosing the activity of pulmonary tuberculosis, the biomarker provides a new target spot for the diagnosis of the active tuberculosis; therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for auxiliary diagnosis of tuberculosis activity.

The invention discloses a gastric cancer risk prediction method and system, computer equipment and a readable storage medium, and relates to the technical field of cancer risk detection. The method comprises the following steps: collecting original data; preprocessing the original data; establishing a risk assessment model and training the risk assessment model; and utilizing the trained risk assessment model to predict a result based on the to-be-tested set. According to the technical scheme provided by the invention, the risk of suffering from gastric cancer can be accurately predicted for reference of doctors.

A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool.

The invention discloses a detection method of an antiphospholipid syndrome related antibody. The detection method combines a microsphere analysis technology and a flow analysis technology, and performs joint detection on 12 antiphospholipid antibody indexes such as aCL-IgG, aCL-IgM, aCL-IgA, beta2-GPI-IgG, beta2-GPI-IgM, beta2-GPI-IgA, PS-IgM, PS-IgG, PI-IgM, PI-IgG, PI-IgM, PI-IgG and the like. The detection method comprises the following steps of: 1) preparing a serum sample; 2) preparing and activating microspheres; 3) preparing a capture antibody; 4) carrying out coupling; 5) performing antigen-antibody combination; 6) carrying out fluorescence labeling reaction; and 7) performing flow type detection. Compared with an existing conventional clinical detection method, the detection method has the advantages that joint detection of 12 antiphospholipid marker antibody indexes for diagnosing the anti-phospholipid syndrome is realized, the required sample size is smaller, the operation time is shorter, multi-parameter analysis can be performed, meanwhile, the specificity and the sensitivity are further extremely high, and the detection level and the standardization degree of the anti-phospholipid antibody index are further improved.

The invention relates to a method and a system for detecting an Rh blood group antigen and application thereof, and belongs to the technical field of biological detection. The invention provides a positive typing method for detecting an Rh blood group antigen based on solid phase adsorption, which comprises the following steps: adding red blood cells to be typed and an Rh blood group antibody into a container coated with second antibodies of other species, performing centrifuging, and observing whether the red blood cells to be typed are adsorbed at the bottom of the container coated with the second antibodies of other species; if the red blood cells to be typed are adsorbed at the bottom of the container coated with the second antibodies of other species, determining that the red blood cells to be typed and Rh blood group antigens corresponding to the Rh blood group antibodies are positive, and if the red blood cells to be typed are not adsorbed at the bottom of the container coated with the second antibodies of other species, determining that the red blood cells to be typed and Rh blood group antigens corresponding to the Rh blood group antibodies are negative. The method is high in sensitivity, strong in specificity and low in detection cost, has the advantage of easiness in automatic operation, and can avoid personal errors in the operation process.

The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer or lung cancer, for monitoring the effectiveness of colorectal cancer or lung cancer treatment, and for drug development.

The invention belongs to the technical field of sperm detection, and particularly relates to a non-diagnostic quantitative detection method for active oxygen of a single sperm and application of the non-diagnostic quantitative detection method. According to the invention, a movable miniature exciting light probe is creatively used and positioned near a single sperm, and a complete detection process is constructed and comprises the steps of processing, positioning, noise reduction, measurement, baseline processing and the like. Finally, the fluorescence intensity emitted by the single sperm is accurately quantified, and the intracellular active oxygen value of the sperm can be accurately given. According to the present invention, the active oxygen detection of the single sperm level is initiated in the field, the field blank is filled, the number of the sperms is not limited, and the method can be suitable for almost all patients including severe oligospermia.

Disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising measuring the level of one or more polyamines in a fluid sample obtained from the subject, measuring at a variable selected from the group consisting of age, prostate volume (PV), prostate-specific antigen (PSA), digital rectal examination (DRE), and combinations thereof. Also disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising obtaining a score value based on previously disclosed variables to predict the likelihood of the subject developing or having prostate cancer.

The present invention relates to methods of predicting the probability of pathological complete response (pCR) of a breast cancer patient upon neo-adjuvant chemotherapy, to methods for selecting a breast cancer treatment, to methods of treatment of breast cancer, and to methods of prognosis of breast cancer upon breast cancer treatment.

The invention belongs to the technical field of oligoasthenozoospermia and asthenozoospermia diagnosis, and particularly relates to application of MYH9 in preparation of a diagnostic reagent for severe oligoasthenozoospermia and asthenozoospermia. On the basis of a proteomics method, protein data in normal and severe oligoasthenozoospermia and asthenozoospermia samples are analyzed, and the protein abundance in the samples is detected by taking BSA protein signal intensity as a standard to obtain differential protein in normal and diseased samples. The MYH9 is detected and confirmed to be significantly up-regulated in severe oligoasthenozoospermia and asthenozoospermia samples through the method, has good credibility, is expected to be used as a detection marker of severe oligoasthenozoospermia and asthenozoospermia, and is applied to development of related detection reagents and kits.

The invention discloses an application of GSK1838705a in ALK + ALCL and crizotinib-resistant ALK + ALCL. GSK1838705a is used for treating tumors, GSK1838705a is used for treating ALK + ALCL, and GSK1838705a is used for treating ALK + ALCL of crizotinib-resistant patients. GSK1838705a can inhibit the proliferation of ALK + ALCL cell line and crizotinib-resistant ALK + ALCL cell line, and induces the apoptosis of the cell line. Compared with the blank control group, GSK1838705a significantly inhibits the expression of p-IGF, p-ALK, p-AKT, p-STATT3 in the ALK + ALCL cell line and the crizotinib-resistant ALK + ALCL cell line, and the expression of activated apoptosis-related proteins is increased significantly. GSK1838705a significantly inhibits the growth of transplanted tumors in mice, andimproves the survival time of transplanted tumor mice, so that GSK1838705a shows anti-tumor effects in the in vivo and in vitro experiments, and a new use for ALK + ALCL and crizotinib-resistant ALK +ALCL is provided.

The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.

A microfluidic blood serum generator having a first port and a second port, between which there is formed a microfluidic structure, wherein the microfluidic structure has a supply duct communicating with the first port, a clotting region into which the supply duct discharges, and a discharge duct which communicates with the second port and into which the clotting region transitions, wherein the first port is designed to introduce a blood sample at a first pressure and the second port is designed to apply a second pressure that is lower than the first pressure, wherein the clotting region is formed by a single, coherent cavity, and wherein a barrier for retaining a clotted blood sample is arranged in the transition from the clotting region to the discharge duct. A method for separating off blood serum from a blood sample using a blood serum generator of this kind.

The invention relates to the technical field of blood disease gene detection, in particular to a kit for detecting blood disease related gene variation. The kit comprises a storage box, a storage cover plate, two hinges, a plurality of storage partition plates, a plurality of drawing boxes, a plurality of drawing partition plates, a plurality of sample test tubes, a plurality of drawing handles and a plurality of taking and placing cover plates. A storage cavity is formed in the storage box, a storage opening is formed in the top of the storage box in a communicating mode, the front side and the rear side of the right side of the storage cover plate are rotationally connected with the front side and the rear side of the top of the left side of the storage box through the two hinges correspondingly, and the storage partition plates are evenly installed in the storage box from front to back. The left ends and the right ends of the multiple storage partition plates are connected with theleft side and the right side of the inner side wall of the storage box correspondingly, and the multiple storage partition plates divide the storage cavity into multiple reagent cavities uniform in size. The storage environment of other samples can be prevented from being affected when gene samples are taken and placed, storage safety of the other samples is guaranteed, and therefore the accuracyof gene detection is guaranteed.

The invention relates to a method for rapidly detecting human body fatigue by using a protein composition in saliva, and belongs to the technical field of human body fatigue detection. The method comprises: determining the fatigue state of a human body by measuring the content of saliva amylase and immunoglobulin K in saliva; wherein the content of the salivary amylase and the immunoglobulin K is in positive correlation with the fatigue state of a human body. According to the non-invasive fatigue marker detection method, the protein marker composition which has good stability and specificity when the human body is in the fatigue state and has the content positively related to the fatigue degree is used for judging whether the human body is fatigue or not and judging the fatigue degree, and the fatigue degree of the human body can be accurately, simply and rapidly determined; and moreover, human tissues cannot be damaged, and the method has the advantages of noninvasive and painless effects and remarkable social significance.